Erratum: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132 (Annals of Surgical Oncology (2011) DOI: 10.1245/S10434-011-2190-5)

Dian Wang, Qiang Zhang, Charles D. Blanke, George D. Demetri, Michael C. Heinrich, James C. Watson, John P. Hoffman, Scott Okuno, John M. Kane, Margaret Von Mehren, Burton L. Eisenberg

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Erratum: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132 (Annals of Surgical Oncology (2011) DOI: 10.1245/S10434-011-2190-5)'. Together they form a unique fingerprint.